New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Ozempic, a type 2 diabetes treatment, presents investment opportunities via Novo Nordisk stock. Projected GLP-1 market growth to almost $160 billion by early the 2030s indicates long-term sector ...

The drugs in development include a pill that a new trial suggests is about as effective as Ozempic. ... medications that they hope will be even more powerful than those currently on the market.

As a more tolerable treatment, it may overtake Ozempic in the weight loss market. "And then there is a third hormone, glucagon," said Kumar. "Paradoxically, ...